The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma
Sarah Brown(University of Leeds), Kwee Yong(CRUK Lung Cancer Centre of Excellence), Walter M. Gregory(University of Leeds), Louise Flanagan(University of Leeds), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Debbie Sherratt(University of Leeds), Martin Kaiser(Royal Marsden NHS Foundation Trust), Samantha Hinsley(University of Leeds), Eric Low(Myeloma UK), Mónica Ballesteros(Universitat Autònoma de Barcelona), Paul McGarry(University of Leeds), Jamie Cavenagh(St Bartholomew's Hospital), Sue Bourne(University of Leeds)
Cited by 9
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Guidelines for the diagnosis and management of adult aplastic anaemia
|British Journal of Haematology|2015|750
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2008|605